Identification of novel follicular dendritic cell sarcoma markers, FDCSP and SRGN, by whole transcriptome sequencing

Luisa Lorenzi, Claudia Döring, Tobias Rausch, Vladimir Benes, Silvia Lonardi, Mattia Bugatti, Elias Campo, José Cabeçadas, Ingrid Simonitsch-Klupp, Anita Borges, Jay Mehta, Claudio Agostinelli, Stefano Aldo Pileri, Fabio Facchetti, Martin Leo Hansmann, Sylvia Hartmann

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Follicular dendritic cell (FDC)-sarcoma is a rare neoplasm with morphologic and phenotypic features of FDCs. It shows an extremely heterogeneous morphology, therefore, its diagnosis relys on the phenotype of tumor cells. Aim of the present study was the identification of new specific markers for FDC-sarcoma by whole transcriptome sequencing (WTS). Candidate markers were selected based on gene expression level and biological function. Immunohistochemistry was performed on reactive tonsils, on 22 cases of FDC-sarcomas and 214 control cases including 114 carcinomas, 87 soft tissue tumors, 5 melanomas, 5 thymomas and 3 interdigitating dendritic cell sarcomas. FDC secreted protein (FDCSP) and Serglycin (SRGN) proved to be specific markers of FDC and related tumor. They showed better specificity and sensitivity values than some well known markers used in FDC sarcoma diagnosis (specificity: 98.6%, and 100%, respectively; sensitivity: 72.73% and 68.18%, respectively). In our cohorts CXCL13, CD21, CD35, FDCSP and SRGN were the best markers for FDC-sarcoma diagnosis and could discriminate 21/22 FDC sarcomas from other mesenchymal tumors by linear discriminant analysis. In summary, by WTS we identified two novel FDC markers and by the analysis of a wide cohort of cases and controls we propose an efficient marker panel for the diagnosis of this rare and enigmatic tumor.

Original languageEnglish
Pages (from-to)16463-16472
Number of pages10
JournalOncotarget
Volume8
Issue number10
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Follicular Dendritic Cell Sarcoma
Transcriptome
Follicular Dendritic Cells
Neoplasms
Proteins
Interdigitating Dendritic Cell Sarcoma
Thymoma
Palatine Tonsil
Discriminant Analysis
serglycin
Melanoma
Immunohistochemistry
Carcinoma
Phenotype
Gene Expression
Sensitivity and Specificity

Keywords

  • Follicular dendritic cell sarcoma
  • Follicular dendritic cell-secreted protein
  • Immunohistochemistry
  • Serglycin
  • Whole transcriptome sequencing

ASJC Scopus subject areas

  • Oncology

Cite this

Lorenzi, L., Döring, C., Rausch, T., Benes, V., Lonardi, S., Bugatti, M., ... Hartmann, S. (2017). Identification of novel follicular dendritic cell sarcoma markers, FDCSP and SRGN, by whole transcriptome sequencing. Oncotarget, 8(10), 16463-16472. https://doi.org/10.18632/oncotarget.14864

Identification of novel follicular dendritic cell sarcoma markers, FDCSP and SRGN, by whole transcriptome sequencing. / Lorenzi, Luisa; Döring, Claudia; Rausch, Tobias; Benes, Vladimir; Lonardi, Silvia; Bugatti, Mattia; Campo, Elias; Cabeçadas, José; Simonitsch-Klupp, Ingrid; Borges, Anita; Mehta, Jay; Agostinelli, Claudio; Pileri, Stefano Aldo; Facchetti, Fabio; Hansmann, Martin Leo; Hartmann, Sylvia.

In: Oncotarget, Vol. 8, No. 10, 01.01.2017, p. 16463-16472.

Research output: Contribution to journalArticle

Lorenzi, L, Döring, C, Rausch, T, Benes, V, Lonardi, S, Bugatti, M, Campo, E, Cabeçadas, J, Simonitsch-Klupp, I, Borges, A, Mehta, J, Agostinelli, C, Pileri, SA, Facchetti, F, Hansmann, ML & Hartmann, S 2017, 'Identification of novel follicular dendritic cell sarcoma markers, FDCSP and SRGN, by whole transcriptome sequencing', Oncotarget, vol. 8, no. 10, pp. 16463-16472. https://doi.org/10.18632/oncotarget.14864
Lorenzi, Luisa ; Döring, Claudia ; Rausch, Tobias ; Benes, Vladimir ; Lonardi, Silvia ; Bugatti, Mattia ; Campo, Elias ; Cabeçadas, José ; Simonitsch-Klupp, Ingrid ; Borges, Anita ; Mehta, Jay ; Agostinelli, Claudio ; Pileri, Stefano Aldo ; Facchetti, Fabio ; Hansmann, Martin Leo ; Hartmann, Sylvia. / Identification of novel follicular dendritic cell sarcoma markers, FDCSP and SRGN, by whole transcriptome sequencing. In: Oncotarget. 2017 ; Vol. 8, No. 10. pp. 16463-16472.
@article{806e75c21ff9479e8022f08b98b0c638,
title = "Identification of novel follicular dendritic cell sarcoma markers, FDCSP and SRGN, by whole transcriptome sequencing",
abstract = "Follicular dendritic cell (FDC)-sarcoma is a rare neoplasm with morphologic and phenotypic features of FDCs. It shows an extremely heterogeneous morphology, therefore, its diagnosis relys on the phenotype of tumor cells. Aim of the present study was the identification of new specific markers for FDC-sarcoma by whole transcriptome sequencing (WTS). Candidate markers were selected based on gene expression level and biological function. Immunohistochemistry was performed on reactive tonsils, on 22 cases of FDC-sarcomas and 214 control cases including 114 carcinomas, 87 soft tissue tumors, 5 melanomas, 5 thymomas and 3 interdigitating dendritic cell sarcomas. FDC secreted protein (FDCSP) and Serglycin (SRGN) proved to be specific markers of FDC and related tumor. They showed better specificity and sensitivity values than some well known markers used in FDC sarcoma diagnosis (specificity: 98.6{\%}, and 100{\%}, respectively; sensitivity: 72.73{\%} and 68.18{\%}, respectively). In our cohorts CXCL13, CD21, CD35, FDCSP and SRGN were the best markers for FDC-sarcoma diagnosis and could discriminate 21/22 FDC sarcomas from other mesenchymal tumors by linear discriminant analysis. In summary, by WTS we identified two novel FDC markers and by the analysis of a wide cohort of cases and controls we propose an efficient marker panel for the diagnosis of this rare and enigmatic tumor.",
keywords = "Follicular dendritic cell sarcoma, Follicular dendritic cell-secreted protein, Immunohistochemistry, Serglycin, Whole transcriptome sequencing",
author = "Luisa Lorenzi and Claudia D{\"o}ring and Tobias Rausch and Vladimir Benes and Silvia Lonardi and Mattia Bugatti and Elias Campo and Jos{\'e} Cabe{\cc}adas and Ingrid Simonitsch-Klupp and Anita Borges and Jay Mehta and Claudio Agostinelli and Pileri, {Stefano Aldo} and Fabio Facchetti and Hansmann, {Martin Leo} and Sylvia Hartmann",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.14864",
language = "English",
volume = "8",
pages = "16463--16472",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "10",

}

TY - JOUR

T1 - Identification of novel follicular dendritic cell sarcoma markers, FDCSP and SRGN, by whole transcriptome sequencing

AU - Lorenzi, Luisa

AU - Döring, Claudia

AU - Rausch, Tobias

AU - Benes, Vladimir

AU - Lonardi, Silvia

AU - Bugatti, Mattia

AU - Campo, Elias

AU - Cabeçadas, José

AU - Simonitsch-Klupp, Ingrid

AU - Borges, Anita

AU - Mehta, Jay

AU - Agostinelli, Claudio

AU - Pileri, Stefano Aldo

AU - Facchetti, Fabio

AU - Hansmann, Martin Leo

AU - Hartmann, Sylvia

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Follicular dendritic cell (FDC)-sarcoma is a rare neoplasm with morphologic and phenotypic features of FDCs. It shows an extremely heterogeneous morphology, therefore, its diagnosis relys on the phenotype of tumor cells. Aim of the present study was the identification of new specific markers for FDC-sarcoma by whole transcriptome sequencing (WTS). Candidate markers were selected based on gene expression level and biological function. Immunohistochemistry was performed on reactive tonsils, on 22 cases of FDC-sarcomas and 214 control cases including 114 carcinomas, 87 soft tissue tumors, 5 melanomas, 5 thymomas and 3 interdigitating dendritic cell sarcomas. FDC secreted protein (FDCSP) and Serglycin (SRGN) proved to be specific markers of FDC and related tumor. They showed better specificity and sensitivity values than some well known markers used in FDC sarcoma diagnosis (specificity: 98.6%, and 100%, respectively; sensitivity: 72.73% and 68.18%, respectively). In our cohorts CXCL13, CD21, CD35, FDCSP and SRGN were the best markers for FDC-sarcoma diagnosis and could discriminate 21/22 FDC sarcomas from other mesenchymal tumors by linear discriminant analysis. In summary, by WTS we identified two novel FDC markers and by the analysis of a wide cohort of cases and controls we propose an efficient marker panel for the diagnosis of this rare and enigmatic tumor.

AB - Follicular dendritic cell (FDC)-sarcoma is a rare neoplasm with morphologic and phenotypic features of FDCs. It shows an extremely heterogeneous morphology, therefore, its diagnosis relys on the phenotype of tumor cells. Aim of the present study was the identification of new specific markers for FDC-sarcoma by whole transcriptome sequencing (WTS). Candidate markers were selected based on gene expression level and biological function. Immunohistochemistry was performed on reactive tonsils, on 22 cases of FDC-sarcomas and 214 control cases including 114 carcinomas, 87 soft tissue tumors, 5 melanomas, 5 thymomas and 3 interdigitating dendritic cell sarcomas. FDC secreted protein (FDCSP) and Serglycin (SRGN) proved to be specific markers of FDC and related tumor. They showed better specificity and sensitivity values than some well known markers used in FDC sarcoma diagnosis (specificity: 98.6%, and 100%, respectively; sensitivity: 72.73% and 68.18%, respectively). In our cohorts CXCL13, CD21, CD35, FDCSP and SRGN were the best markers for FDC-sarcoma diagnosis and could discriminate 21/22 FDC sarcomas from other mesenchymal tumors by linear discriminant analysis. In summary, by WTS we identified two novel FDC markers and by the analysis of a wide cohort of cases and controls we propose an efficient marker panel for the diagnosis of this rare and enigmatic tumor.

KW - Follicular dendritic cell sarcoma

KW - Follicular dendritic cell-secreted protein

KW - Immunohistochemistry

KW - Serglycin

KW - Whole transcriptome sequencing

UR - http://www.scopus.com/inward/record.url?scp=85014622311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014622311&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.14864

DO - 10.18632/oncotarget.14864

M3 - Article

VL - 8

SP - 16463

EP - 16472

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 10

ER -